## Robert D Inman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4669671/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bridging the Gap Between Symptom Onset and Diagnosis in Axial Spondyloarthritis. Arthritis Care and Research, 2022, 74, 997-1005.	3.4	5
2	Exploring sex differences in alpha brain activity as a potential neuromarker associated with neuropathic pain. Pain, 2022, 163, 1291-1302.	4.2	12
3	Motivators, barriers, and opportunity for eâ€health to encourage physical activity in axial spondyloarthritis: a qualitative descriptive study. Arthritis Care and Research, 2022, 74, 50-58.	3.4	3
4	Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology, 2022, 61, 3299-3308.	1.9	16
5	Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases, 2022, 81, 1515-1523.	0.9	43
6	The role of LCN2 and LCN2-MMP9 in spondylitis radiographic development: gender and HLA-B27 status differences. Arthritis Research and Therapy, 2022, 24, .	3.5	2
7	Response to: â€ <sup>-</sup> Gut-derived CD8+ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients' by Guggino <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e175-e175.	0.9	0
8	Tumor Necrosis Factor Inhibitor Dose Reduction for Axial Spondyloarthritis: A Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Arthritis Care and Research, 2021, 73, 861-872.	3.4	12
9	Abnormal subgenual anterior cingulate circuitry is unique to women but not men with chronic pain. Pain, 2021, 162, 97-108.	4.2	14
10	Factors Predictive of Radiographic Progression in Ankylosing Spondylitis. Arthritis Care and Research, 2021, 73, 275-281.	3.4	10
11	Recent advances on the role of cytotoxic T lymphocytes in the pathogenesis of spondyloarthritis. Seminars in Immunopathology, 2021, 43, 255-264.	6.1	3
12	The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights. Seminars in Immunopathology, 2021, 43, 173-192.	6.1	28
13	Axial Spondyloarthritis: Current Advances, Future Challenges. Journal of Rheumatic Diseases, 2021, 28, 55-59.	1.1	30
14	Pain in Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2021, 47, 197-213.	1.9	6
15	Serial Lipocalin 2 and Oncostatin M levels reflect inflammation status and treatment response in axial spondyloarthritis. Arthritis Research and Therapy, 2021, 23, 141.	3.5	7
16	Gut microbiota–microRNA interactions in ankylosing spondylitis. Autoimmunity Reviews, 2021, 20, 102827.	5.8	13
17	From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. Frontiers in Genetics, 2021, 12, 685280.	2.3	16
18	IgG4-related Disease in a Patient With Ankylosing Spondylitis: Clues to Common Immunopathogenesis. Journal of Rheumatology, 2021, 48, jrheum.201552.	2.0	0

#	Article	IF	CITATIONS
19	Sex differences in brain modular organization in chronic pain. Pain, 2021, 162, 1188-1200.	4.2	24
20	Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. Science Translational Medicine, 2021, 13, eabg1210.	12.4	28
21	Advancing Early Identification of Axial Spondyloarthritis: An Interobserver Comparison of Extended Role Practitioners and Rheumatologists. Journal of Rheumatology, 2020, 47, 524-530.	2.0	7
22	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. Rheumatology, 2020, 59, 1340-1346.	1.9	88
23	Altered Cytotoxicity Profile of <scp>CD</scp> 8+ T Cells in Ankylosing Spondylitis. Arthritis and Rheumatology, 2020, 72, 428-434.	5.6	38
24	Abnormal alpha band power in the dynamic pain connectome is a marker of chronic pain with a neuropathic component. NeuroImage: Clinical, 2020, 26, 102241.	2.7	30
25	Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS). Arthritis Research and Therapy, 2020, 22, 51.	3.5	8
26	HLA, Immune Response, and Susceptibility to COVID-19. Frontiers in Immunology, 2020, 11, 601886.	4.8	72
27	TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. Journal of Clinical Investigation, 2020, 130, 1863-1878.	8.2	51
28	Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatology and Therapy, 2019, 6, 435-450.	2.3	16
29	Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Annals of the Rheumatic Diseases, 2019, 78, 1566-1575.	0.9	53
30	The Prevalence and Clinical Associations of Subclinical Sacroiliitis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1066-1071.	1.9	20
31	The ties that bind: skin, gut and spondyloarthritis. Current Opinion in Rheumatology, 2019, 31, 62-69.	4.3	36
32	Pathophysiology of Reactive Arthritis. , 2019, , 345-353.		0
33	Multivariate machine learning distinguishes cross-network dynamic functional connectivity patterns in state and trait neuropathic pain. Pain, 2018, 159, 1764-1776.	4.2	41
34	Patients with chronic pain exhibit a complex relationship triad between pain, resilience, and within- and cross-network functional connectivity of the default mode network. Pain, 2018, 159, 1621-1630.	4.2	54
35	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
36	Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized Computed Tomography Scoring System. Arthritis Care and Research, 2018, 70, 807-810.	3.4	25

#	Article	IF	CITATIONS
37	Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis. Arthritis Care and Research, 2018, 70, 1393-1399.	3.4	10
38	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet, The, 2018, 392, 134-144.	13.7	81
39	Abnormal Low-Frequency Oscillations Reflect Trait-Like Pain Ratings in Chronic Pain Patients Revealed through a Machine Learning Approach. Journal of Neuroscience, 2018, 38, 7293-7302.	3.6	34
40	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nature Reviews Rheumatology, 2018, 14, 363-371.	8.0	149
41	AB0864â€The impact of disease activity, structural damage, and fatigue on physical function in patients with ankylosing spondylitis: differences in early and late disease. , 2018, , .		Ο
42	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.9	1,220
43	Pathogenesis of ankylosing spondylitis — recent advances and future directions. Nature Reviews Rheumatology, 2017, 13, 359-367.	8.0	238
44	Pain in ankylosing spondylitis: a neuro-immune collaboration. Nature Reviews Rheumatology, 2017, 13, 410-420.	8.0	54
45	Discovery of T Cell Receptor β Motifs Specific to HLA–B27–Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis. Arthritis and Rheumatology, 2017, 69, 774-784.	5.6	74
46	Analysis of dedicated sacroiliac views to improve reliability of conventional pelvic radiographs. Rheumatology, 2017, 56, 1740-1745.	1.9	17
47	Infection with the Lyme disease pathogen suppresses innate immunity in mice with diet-induced obesity. Cellular Microbiology, 2017, 19, e12689.	2.1	17
48	THU0388â€Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results from the 28-week open-label period of the ability-3 study. , 2017, , .		0
49	Pain in spondyloarthritis: A neuro–immune interaction. Best Practice and Research in Clinical Rheumatology, 2017, 31, 830-845.	3.3	12
50	Validity of ankylosing spondylitis diagnoses in The Health Improvement Network. Pharmacoepidemiology and Drug Safety, 2016, 25, 399-404.	1.9	35
51	Clinical Efficacy of Celecoxib Compared to Acetaminophen in Chronic Nonspecific Low Back Pain: Results of a Randomized Controlled Trial. Arthritis Care and Research, 2016, 68, 845-852.	3.4	27
52	IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2016, 75, 2124-2132.	0.9	234
53	Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Research and Therapy, 2016, 18, 304.	3.5	30
54	Su1832 Sacroiliitis is underrecognized in Inflammatory Bowel Disease and is Associated With Previous Arthritis and Inflammatory Crohn's Phenotype. Gastroenterology, 2016, 150, S565.	1.3	0

#	Article	IF	CITATIONS
55	Development of a Screening Tool for the Identification of Sacroiliitis in Computed Tomography Scans of the Abdomen. Journal of Rheumatology, 2016, 43, 1687-1694.	2.0	15
56	CCL19-CCR7–dependent reverse transendothelial migration of myeloid cells clears Chlamydia muridarum from the arterial intima. Nature Immunology, 2016, 17, 1263-1272.	14.5	34
57	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research, 2016, 68, 151-166.	3.4	53
58	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2016, 68, 282-298.	5.6	383
59	Gamma Delta T Cell Subset V Gamma 2+ Expansion Associated with Longterm Infliximab Treatment in a Patient with Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 2079.2-2082.	2.0	3
60	Sexual Dimorphism in the Th17 Signature of Ankylosing Spondylitis. Arthritis and Rheumatology, 2016, 68, 679-689.	5.6	129
61	Varicella-Zoster Virus in Giant Cell Arteritis. JAMA Neurology, 2016, 73, 238.	9.0	Ο
62	Abnormal cross-network functional connectivity in chronic pain and its association with clinical symptoms. Brain Structure and Function, 2016, 221, 4203-4219.	2.3	163
63	Private rare deletions in <i>SEC16A</i> and <i>MAMDC4</i> may represent novel pathogenic variants in familial axial spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 772-779.	0.9	17
64	Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality. Annals of Internal Medicine, 2015, 163, 409-416.	3.9	199
65	SAT0233â€Acute Anterior Uveitis in Ankylosing Spondylitis: Association with Inflammatory Bowel Disease and Psoriasis Independent of HLA-B27. Annals of the Rheumatic Diseases, 2015, 74, 743.1-743.	0.9	0
66	Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis. Arthritis Research and Therapy, 2015, 17, 377.	3.5	29
67	Pulmonary <i>Chlamydia muridarum</i> challenge activates lung interstitial macrophages which correlate with IFNâ€Î³ production and infection control in mice. European Journal of Immunology, 2015, 45, 3417-3430.	2.9	9
68	THU0582â€Readability of Online Ankylosing Spondylitis Patient Education Material. Annals of the Rheumatic Diseases, 2015, 74, 411.1-411.	0.9	0
69	Tumor necrosis factor inhibitor therapy in ankylosing spondylitis. Pain, 2015, 156, 297-304.	4.2	47
70	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications, 2015, 6, 7146.	12.8	220
71	Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort. Journal of Rheumatology, 2015, 42, 2354-2360.	2.0	44
72	Golimumab administered subcutaneously every 4â€weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Annals of the Rheumatic Diseases, 2015, 74, 757-761.	0.9	92

Robert D Inman

#	Article	IF	CITATIONS
73	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. Journal of Rheumatology, 2015, 42, 665-681.	2.0	42
74	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada. Journal of Rheumatology, 2015, 42, 654-664.	2.0	39
75	<i>ERAP2</i> is associated with ankylosing spondylitis in <i>HLA-B27</i> -positive and <i>HLA-B27-</i> negative patients. Annals of the Rheumatic Diseases, 2015, 74, 1627-1629.	0.9	86
76	Bone Lineage Proteins in the Entheses of the Midfoot in Patients with Spondyloarthritis. Journal of Rheumatology, 2015, 42, 630-637.	2.0	17
77	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Annals of the Rheumatic Diseases, 2015, 74, 1051-1057.	0.9	128
78	Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology, 2015, 54, 152-156.	1.9	37
79	Heritability of spinal curvature and its relationship to disc degeneration and bone mineral density in female adult twins. European Spine Journal, 2015, 24, 2387-2394.	2.2	26
80	Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and Differences in Associations Observed With Ankylosing Spondylitis. Arthritis and Rheumatology, 2015, 67, 140-151.	5.6	114
81	Reactive arthritis. , 2015, , 928-940.		1
82	Ocular inflammation in HLA-B27 transgenic mice reveals a potential role for MHC class I in corneal immune privilege. Molecular Vision, 2015, 21, 131-7.	1.1	4
83	Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1873-1879.	0.9	58
84	The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4â€years of the GO-RAISE trial. Annals of the Rheumatic Diseases, 2014, 73, 1107-1113.	0.9	105
85	Development and Validation of the Spondyloarthritis Radiography Module for Calibration of Readers Using the Modified Stoke Ankylosing Spondylitis Spine Score. Arthritis Care and Research, 2014, 66, 55-62.	3.4	12
86	Microbiome and probiotics. Current Opinion in Rheumatology, 2014, 26, 410-415.	4.3	22
87	The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial. Journal of Rheumatology, 2014, 41, 1095-1103.	2.0	41
88	Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2014, 44, 155-161.	3.4	61
89	HLA-B27, but Not HLA-B7, Immunodominance to Influenza Is ERAP Dependent. Journal of Immunology, 2014, 192, 5520-5528.	0.8	32
90	Editorial: HLA–B27, Cytokines, and Spondyloarthritis: Noncanonical Functions of a Curious Class I Major Histocompatibility Complex Gene. Arthritis and Rheumatology, 2014, 66, 783-785.	5.6	3

#	Article	IF	CITATIONS
91	Recognition of Preclinical and Early Disease in Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2014, 40, 685-697.	1.9	10
92	Analysis of the Effect of the Oral Contraceptive Pill on Clinical Outcomes in Women with Ankylosing Spondylitis. Journal of Rheumatology, 2014, 41, 1344-1348.	2.0	10
93	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. Arthritis and Rheumatology, 2014, 66, 2649-2656.	5.6	81
94	Fatigue in Ankylosing Spondylitis Is Associated With the Brain Networks of Sensory Salience and Attention. Arthritis and Rheumatology, 2014, 66, 295-303.	5.6	28
95	The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. The Application of Clinical Genetics, 2014, 7, 105.	3.0	86
96	FRI0161â€Sec16a Gene Deletion in A Large Axial Spondyloarthritis Family. Annals of the Rheumatic Diseases, 2014, 73, 440.2-440.	0.9	0
97	Bone Morphogenetic Protein 6 Polymorphisms Are Associated with Radiographic Progression in Ankylosing Spondylitis. PLoS ONE, 2014, 9, e104966.	2.5	24
98	The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 2645-2654.	6.7	391
99	Imaging of Spondyloarthropathies. Rheumatic Disease Clinics of North America, 2013, 39, 645-667.	1.9	6
100	Coâ€expression of <scp>HLA</scp> â€ <scp>B</scp> 7 and <scp>HLA</scp> â€ <scp>B</scp> 27 alleles is associated with <scp>B</scp> 7â€restricted immunodominant responses following influenza infection. European Journal of Immunology, 2013, 43, 3254-3267.	2.9	14
101	UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family. BMC Genetics, 2013, 14, 67.	2.7	19
102	Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology, 2013, 52, 321-325.	1.9	28
103	Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Part of a Common Spectrum or Distinct Diseases?. Journal of Rheumatology, 2013, 40, 2038-2041.	2.0	78
104	Secondary amyloidosis in ankylosing spondylitis. Rheumatology International, 2013, 33, 1725-1729.	3.0	24
105	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genetics, 2013, 45, 730-738.	21.4	699
106	In Memoriam – Duncan A. Gordon, 1930–2012. Journal of Rheumatology, 2013, 40, 209-213.	2.0	0
107	Antibiotics for Treatment of Reactive Arthritis: A Systematic Review and Metaanalysis. Journal of Rheumatology, 2013, 40, 916-928.	2.0	54
108	Neuropathic Pain in Ankylosing Spondylitis: A Psychophysics and Brain Imaging Study. Arthritis and Rheumatism, 2013, 65, 1494-1503.	6.7	103

#	Article	IF	CITATIONS
109	Development, Sensibility, and Reliability of the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease. Journal of Rheumatology, 2013, 40, 1726-1735.	2.0	20
110	Ankylosing Spondylitis Clinical Registries: Principles, Practices and Possibilities. American Journal of the Medical Sciences, 2013, 345, 437-439.	1.1	5
111	Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study. Arthritis Research and Therapy, 2013, 15, R166.	3.5	56
112	Intervertebral Disc-Derived Stem Cells. Spine, 2013, 38, 211-216.	2.0	67
113	Intracellular Survival and Persistence of Chlamydia muridarum Is Determined by Macrophage Polarization. PLoS ONE, 2013, 8, e69421.	2.5	44
114	Pathogenesis of Ankylosing Spondylitis and Reactive Arthritis. , 2013, , 1193-1201.		1
115	Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Annals of the Rheumatic Diseases, 2012, 71, 674-680.	0.9	24
116	Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nature Reviews Rheumatology, 2012, 8, 55-59.	8.0	20
117	Aberrant Chondrocyte Hypertrophy and Activation of ß-Catenin Signaling Precede Joint Ankylosis in ank/ank Mice. Journal of Rheumatology, 2012, 39, 583-593.	2.0	14
118	Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Annals of the Rheumatic Diseases, 2012, 71, 878-884.	0.9	72
119	Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the Rheumatic Diseases, 2012, 71, 661-667.	0.9	92
120	The "Knowns―and "Unknowns―of Biologic Therapy in Ankylosing Spondylitis. American Journal of the Medical Sciences, 2012, 343, 360-363.	1.1	4
121	Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placeboâ€controlled study. Arthritis Care and Research, 2012, 64, 1919-1922.	3.4	19
122	Reactive Arthritis: Developments and Challenges in Diagnosis and Treatment. Current Rheumatology Reports, 2012, 14, 390-394.	4.7	37
123	NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms?. Annals of the Rheumatic Diseases, 2012, 71, 1593-1595.	0.9	40
124	Postural control is altered in patients with ankylosing spondylitis. Clinical Biomechanics, 2012, 27, 334-340.	1.2	38
125	<i>Chlamydia trachomatis</i> vacuole maturation in infected macrophages. Journal of Leukocyte Biology, 2012, 92, 815-827.	3.3	39
126	Chlamydia and chronic arthritis. Annals of Medicine, 2012, 44, 784-792.	3.8	31

#	Article	IF	CITATIONS
127	Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis. Arthritis Research and Therapy, 2012, 14, R150.	3.5	10
128	The Spondyloarthropathies. , 2012, , 1690-1697.		3
129	Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis and Rheumatism, 2012, 64, 1119-1126.	6.7	38
130	Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 589-595.	0.9	82
131	Immunodominance: A pivotal principle in host response to viral infections. Clinical Immunology, 2012, 143, 99-115.	3.2	101
132	Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. Journal of Translational Medicine, 2012, 10, 19.	4.4	38
133	The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis. Scandinavian Journal of Rheumatology, 2011, 40, 269-278.	1.1	34
134	Aberrant axial mineralization precedes spinal ankylosis: a molecular imaging study in ank/ank mice. Arthritis Research and Therapy, 2011, 13, R163.	3.5	2
135	Subluxation atloido-axoÃ⁻dienne, manifestation inaugurale de trois cas de spondylarthropathie. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 476-478.	0.0	0
136	Atlanto-axial subluxation as the initial manifestation of spondyloarthritis. Joint Bone Spine, 2011, 78, 415-417.	1.6	9
137	Chlamydia-induced reactive arthritis: Hidden in plain sight?. Best Practice and Research in Clinical Rheumatology, 2011, 25, 359-374.	3.3	28
138	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, 43, 761-767.	21.4	778
139	T-cell responses to versican in ankylosing spondylitis. Rheumatology International, 2011, 31, 191-195.	3.0	5
140	Notochordal cells protect nucleus pulposus cells from degradation and apoptosis: implications for the mechanisms of intervertebral disc degeneration. Arthritis Research and Therapy, 2011, 13, R215.	3.5	129
141	Predicting the outcome of ankylosing spondylitis therapy. Annals of the Rheumatic Diseases, 2011, 70, 973-981.	0.9	158
142	Clinical Correlates of Urolithiasis in Ankylosing Spondylitis. Journal of Rheumatology, 2011, 38, 1953-1956.	2.0	9
143	Genetic Studies of Ankylosing Spondylitis in Koreans Confirm Associations with <i>ERAP1</i> and 2p15 Reported in White Patients. Journal of Rheumatology, 2011, 38, 322-324.	2.0	36
144	Measuring participation in people with spondyloarthritis using the social role participation questionnaire. Annals of the Rheumatic Diseases, 2011, 70, 1765-1769.	0.9	20

#	Article	IF	CITATIONS
145	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. Journal of Rheumatology, 2011, 38, 1343-1348.	2.0	16
146	Effect of Pregnancy on Ankylosing Spondylitis: A Case-Control Study. Journal of Rheumatology, 2011, 38, 2442-2444.	2.0	39
147	Reactive arthritis. , 2011, , 1103-1112.e3.		1
148	Inflammatory and degenerative sacroiliac joint disease in a primary back pain cohort. Arthritis Care and Research, 2010, 62, 447-454.	3.4	60
149	Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placeboâ€controlled trial. Arthritis Care and Research, 2010, 62, 1266-1271.	3.4	50
150	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nature Genetics, 2010, 42, 123-127.	21.4	573
151	Visual Assessment of the Spine Bruckel Instrument, a Novel Status Tool to Reflect Appearance of the Spine in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 628-632.	2.0	0
152	Low-dose Infliximab (3 mg/kg) Significantly Reduces Spinal Inflammation on Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis: A Randomized Placebo-controlled Study. Journal of Rheumatology, 2010, 37, 1728-1734.	2.0	49
153	The Genetic Basis of Spondyloarthritis: SPARTAN/IGAS 2009. Journal of Rheumatology, 2010, 37, 2626-2631.	2.0	4
154	Endoplasmic reticulum aminopeptidases: biology and pathogenic potential. Nature Reviews Rheumatology, 2010, 6, 461-467.	8.0	93
155	Serum Cytokine Receptors in Ankylosing Spondylitis: Relationship to Inflammatory Markers and Endoplasmic Reticulum Aminopeptidase Polymorphisms. Journal of Rheumatology, 2010, 37, 1907-1910.	2.0	46
156	Treatment of Autoimmune Arthritis Using RNA Interference-Modulated Dendritic Cells. Journal of Immunology, 2010, 184, 6457-6464.	0.8	63
157	ARTS1 polymorphisms are associated with ankylosing spondylitis in Koreans. Annals of the Rheumatic Diseases, 2010, 69, 582-584.	0.9	54
158	Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Annals of the Rheumatic Diseases, 2010, 69, 733-736.	0.9	97
159	Bone Marrow-derived Human Hematopoietic Stem Cells Engraft NOD/SCID Mice and Traffic Appropriately to an Inflammatory Stimulus in the Joint. Journal of Rheumatology, 2010, 37, 496-502.	2.0	10
160	Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease. PLoS Genetics, 2010, 6, e1001195.	3.5	183
161	Assessing Back Pain: Does the Oswestry Disability Questionnaire Accurately Measure Function in Ankylosing Spondylitis?. Journal of Rheumatology, 2010, 37, 1211-1213.	2.0	5
162	Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2010, 69, 1264-1268.	0.9	71

Robert D Inman

#	Article	IF	CITATIONS
163	A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 1203-1210.	2.0	73
164	Exercise in Ankylosing Spondylitis: Discrepancies Between Recommendations and Reality. Journal of Rheumatology, 2010, 37, 835-841.	2.0	54
165	RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Research and Therapy, 2010, 12, R13.	3.5	45
166	Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences. Journal of rheumatology Supplement, The, 2010, 85, 11-26.	2.2	33
167	Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 137-140.	2.0	72
168	Significance of Clinical Evaluation of the Metacarpophalangeal Joint in Relation to Synovial/Bone Pathology in Rheumatoid and Psoriatic Arthritis Detected by Magnetic Resonance Imaging. Journal of Rheumatology, 2009, 36, 2751-2757.	2.0	20
169	Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis. Nature Reviews Rheumatology, 2009, 5, 171-173.	8.0	4
170	The regenerative capacity of the notochordal cell: tissue constructs generated in vitro under hypoxic conditions. Journal of Neurosurgery: Spine, 2009, 10, 513-521.	1.7	36
171	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. Journal of Rheumatology, 2009, 36, 1792-1799.	2.0	38
172	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. Journal of Rheumatology, 2009, 36, 1785-1791.	2.0	40
173	Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. Journal of Rheumatology, 2009, 36, 1769-1784.	2.0	21
174	IL-23R Polymorphisms in Patients with Ankylosing Spondylitis in Korea: Table 1 Journal of Rheumatology, 2009, 36, 1003-1005.	2.0	42
175	Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. International Immunology, 2009, 21, 859-870.	4.0	17
176	Contribution of phosphatidylserine to membrane surface charge and protein targeting during phagosome maturation. Journal of Cell Biology, 2009, 185, 917-928.	5.2	120
177	Acetabular labral tear mimicking seronegative arthritis in a young male. Arthritis and Rheumatism, 2009, 61, 850-852.	6.7	1
178	Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis and Rheumatism, 2009, 61, 1032-1036.	6.7	32
179	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the Rheumatic Diseases, 2009, 68, 770-776.	0.9	731
180	Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. Vaccine, 2009, 27, 5432-5434.	3.8	5

#	Article	IF	CITATIONS
181	Heavy metal exposure reverses genetic resistance to Chlamydia-induced arthritis. Arthritis Research and Therapy, 2009, 11, R19.	3.5	13
182	Infectious complications of biological therapy. Current Opinion in Rheumatology, 2009, 21, 397-403.	4.3	20
183	Innate Immunity of Spondyloarthritis: The Role of Toll-Like Receptors. Advances in Experimental Medicine and Biology, 2009, 649, 300-309.	1.6	9
184	Reactive Arthritis. , 2009, , 73-76.		0
185	Analysis of single nucleotide polymorphisms in Toll-like receptor 4 shows no association with ankylosing spondylitis in a Korean population. Rheumatology International, 2008, 28, 627-630.	3.0	19
186	Association of interleukinâ€⊋3 receptor variants with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 58, 1020-1025.	6.7	152
187	Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferonâ€Î³ dysregulation. Arthritis and Rheumatism, 2008, 58, 1640-1649.	6.7	87
188	Tollâ€like receptor 2 variants are associated with acute reactive arthritis. Arthritis and Rheumatism, 2008, 58, 3436-3438.	6.7	52
189	Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, doubleâ€blind, placeboâ€controlled, phase III trial. Arthritis and Rheumatism, 2008, 58, 3402-3412.	6.7	512
190	Reactive and Enteropathic Arthritis. , 2008, , 217-223.		0
191	Antigen-specific therapy of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2008, 8, 191-199.	3.1	10
192	The ANKH ΔE490 Mutation in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease (CPPDD) Affects Tissue Non-specific Alkaline Phosphatase (TNAP) Activities. Open Rheumatology Journal, 2008, 2, 23-30.	0.2	11
193	Interleukin 1 polymorphisms in patients with ankylosing spondylitis in Korea. Journal of Rheumatology, 2008, 35, 1603-8.	2.0	19
194	Symptomatic acute reactive arthritis after an outbreak of salmonella. Journal of Rheumatology, 2008, 35, 1599-602.	2.0	38
195	Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2007, 67, 1305-1309.	0.9	103
196	Association of aTNAP haplotype with ankylosing spondylitis. Arthritis and Rheumatism, 2007, 56, 234-243.	6.7	27
197	Validation of the Spondyloarthritis Research Consortium of Canada magnetic resonance imaging spinal inflammation index: Is it necessary to score the entire spine?. Arthritis and Rheumatism, 2007, 57, 501-507.	6.7	64
198	Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, doubleâ€blind, placeboâ€controlled study. Arthritis and Rheumatism, 2007, 56, 4005-4014.	6.7	242

#	Article	IF	CITATIONS
199	Microcytosis in ank/ank mice and the role of ANKH in promoting erythroid differentiation. Experimental Cell Research, 2007, 313, 4120-4129.	2.6	9
200	Chlamydia -Induced Arthritis. , 2007, , 156-160.		0
201	International spondyloarthritis interobserver reliability exercisethe INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. Journal of Rheumatology, 2007, 34, 1740-5.	2.0	74
202	Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Research and Therapy, 2006, 8, R141.	3.5	67
203	Notochord Cells Regulate Intervertebral Disc Chondrocyte Proteoglycan Production and Cell Proliferation. Spine, 2006, 31, 1094-1099.	2.0	102
204	Altered host:pathogen interactions conferred by the Blau syndrome mutation of NOD2. Rheumatology International, 2006, 27, 257-262.	3.0	13
205	Biomarkers in spondyloarthritis. Current Rheumatology Reports, 2006, 8, 283-286.	4.7	3
206	Reactive arthritis or post-infectious arthritis?. Best Practice and Research in Clinical Rheumatology, 2006, 20, 419-433.	3.3	100
207	Association of theIL1 gene cluster with susceptibility to ankylosing spondylitis: An analysis of three Canadian populations. Arthritis and Rheumatism, 2006, 54, 974-985.	6.7	69
208	Early cytokine profiles in the joint define pathogen clearance and severity of arthritis inChlamydia-induced arthritis in rats. Arthritis and Rheumatism, 2006, 54, 499-507.	6.7	48
209	Biomarkers in spondylarthritis: A peripheral vision. Arthritis and Rheumatism, 2006, 54, 1733-1735.	6.7	1
210	Conundrums in nosology: Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and spondylarthritis. Arthritis and Rheumatism, 2006, 55, 665-669.	6.7	67
211	Nucleus pulposus notochord cells secrete connective tissue growth factor and Up-regulate proteoglycan expression by intervertebral disc chondrocytes. Arthritis and Rheumatism, 2006, 54, 3859-3867.	6.7	128
212	Pulmonary sarcoidosis developing during infliximab therapy. Arthritis and Rheumatism, 2006, 55, 978-981.	6.7	78
213	Mechanisms of Disease: infection and spondyloarthritis. Nature Clinical Practice Rheumatology, 2006, 2, 163-169.	3.2	29
214	Infection and Spondyloarthritis. , 2006, , 38-52.		3
215	Pathogenesis of ankylosing spondylitis and reactive arthritis. Current Opinion in Rheumatology, 2005, 17, 400-405.	4.3	71
216	Cartilage biomarkers in ankylosing spondylitis: Relationship to clinical variables and treatment response. Arthritis and Rheumatism, 2005, 52, 885-891.	6.7	49

#	Article	IF	CITATIONS
217	Innate immunity and arthritis: Neutrophil Rac and toll-like receptor 4 expression define outcomes in infection-triggered arthritis. Arthritis and Rheumatism, 2005, 52, 1297-1304.	6.7	51
218	Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis and Rheumatism, 2005, 53, 445-451.	6.7	108
219	Spondyloarthritis research consortium of canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis and Rheumatism, 2005, 53, 502-509.	6.7	203
220	Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis and Rheumatism, 2005, 53, 703-709.	6.7	407
221	Accumulation of Diacylglycerol in the Chlamydia Inclusion Vacuole. Journal of Biological Chemistry, 2005, 280, 25210-25215.	3.4	38
222	Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity. British Journal of Rheumatology, 2005, 44, 55-60.	2.3	12
223	ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Research, 2005, 7, R513.	2.0	66
224	Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. Journal of Rheumatology, 2005, 32, 1907-10.	2.0	21
225	Synovial Fibroblasts Infected with Salmonella enterica Serovar Typhimurium Mediate Osteoclast Differentiation and Activation. Infection and Immunity, 2004, 72, 7183-7189.	2.2	20
226	Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis and Rheumatism, 2004, 50, 2246-2254.	6.7	109
227	Lack of linkage ofIL1RN genotypes with ankylosing spondylitis susceptibility. Arthritis and Rheumatism, 2004, 50, 3047-3048.	6.7	22
228	Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in western populations. Journal of Rheumatology, 2004, 31, 1959-61.	2.0	17
229	Novel genetic markers in the 5?-flanking region ofANKH are associated with ankylosing spondylitis. Arthritis and Rheumatism, 2003, 48, 791-797.	6.7	57
230	Microbe hunting in the joints. Arthritis and Rheumatism, 2003, 49, 479-482.	6.7	19
231	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis and Rheumatism, 2003, 48, 3230-3236.	6.7	707
232	Differential Role of Actin, Clathrin, and Dynamin in Fcl <sup>3</sup> Receptor-mediated Endocytosis and Phagocytosis. Journal of Biological Chemistry, 2003, 278, 3331-3338.	3.4	106
233	Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Current Opinion in Rheumatology, 2003, 15, 387-393.	4.3	51
234	Determinants of synoviocyte clearance of arthritogenic bacteria. Journal of Rheumatology, 2003, 30, 1291-7.	2.0	18

#	Article	IF	CITATIONS
235	Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. Journal of Rheumatology, 2003, 30, 2112-22.	2.0	86
236	Breakdown of CTL Tolerance to Self HLA-B*2705 Induced by Exposure toChlamydiatrachomatis. Journal of Immunology, 2002, 169, 4033-4038.	0.8	38
237	Cleavage of the Carboxyl Tail from the G3 Domain of Aggrecan but Not Versican and Identification of the Amino Acids Involved in the Degradation. Journal of Biological Chemistry, 2002, 277, 22279-22288.	3.4	10
238	Innate immunity in host-microbial interactions: Beyond B27 in the spondyloarthropathies. Current Opinion in Rheumatology, 2002, 14, 373-382.	4.3	20
239	Retroperitoneal fibrosis: An extraarticular manifestation of ankylosing spondylitis. Arthritis and Rheumatism, 2002, 47, 210-214.	6.7	25
240	Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver, 2002, 22, 228-234.	0.1	77
241	Infectious agents in chronic rheumatic diseases. Current Opinion in Rheumatology, 2001, 13, 300-304.	4.3	24
242	Clinical stratification in the spondylarthropathies: E pluribus unum or ex uno plures?. Arthritis and Rheumatism, 2001, 45, 475-477.	6.7	3
243	The Effect of an Anti-HLA-B27 Immune Response on CTL Recognition ofChlamydia. Journal of Immunology, 2001, 167, 3375-3382.	0.8	24
244	SP0031â€Genetic studies in familial ankylosing spondylitis: the north american spondylitis consortium experience. , 2001, , .		0
245	Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. Journal of Rheumatology, 2001, 28, 1605-14.	2.0	85
246	Chlamydia and associated arthritis. Current Opinion in Rheumatology, 2000, 12, 254-262.	4.3	76
247	Recent developments in the therapy of spondyloarthropathies. Current Rheumatology Reports, 2000, 2, 279-281.	4.7	1
248	Tumor Necrosis Factor Receptor p55-Deficient Mice Respond to Acute Yersinia enterocolitica Infection with Less Apoptosis and More Effective Host Resistance. Infection and Immunity, 2000, 68, 1243-1251.	2.2	28
249	Gram-negative pathogens and molecular mimicry: is there a case for mistaken identity?. Trends in Microbiology, 2000, 8, 444-445.	7.7	4
250	Molecular Mimicry and Autoimmunity. New England Journal of Medicine, 1999, 341, 2068-2074.	27.0	455
251	Tumor necrosis factor receptor p55 controls the severity of arthritis in experimental Yersinia enterocolitica infection. Arthritis and Rheumatism, 1999, 42, 1662-1672.	6.7	15
252	Rodent models of lymphocyte migration. Seminars in Immunology, 1999, 11, 85-93.	5.6	15

#	Article	IF	CITATIONS
253	Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A department of veterans affairs cooperative study. Arthritis and Rheumatism, 1996, 39, 2021-2027.	6.7	136
254	Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Current Opinion in Rheumatology, 1995, 7, 290-298.	4.3	9
255	Acute anterior uveitis: Clinical and experimental aspects. Seminars in Arthritis and Rheumatism, 1995, 24, 432-441.	3.4	22
256	Post-Salmonella reactive arthritis: Late clinical sequelae in a point source cohort. American Journal of Medicine, 1995, 98, 13-21.	1.5	91
257	Concise communication. Arthritis and Rheumatism, 1994, 37, 1411-1411.	6.7	2
258	Arthropathy in thalassaemia patients receiving deferiprone. Lancet, The, 1994, 343, 1471-1472.	13.7	63
259	Etiopathogenesis of ankylosing spondylitis and reactive arthritis. Current Opinion in Rheumatology, 1994, 6, 360-370.	4.3	62
260	Infectious agents and other nongenetic immunologic factors in spondyloarthropathies. Current Opinion in Rheumatology, 1991, 3, 581-585.	4.3	2
261	Infectious Etiology of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 1991, 17, 859-870.	1.9	17
262	Antigens, the Gastrointestinal Tract, and Arthritis. Rheumatic Disease Clinics of North America, 1991, 17, 309-321.	1.9	9
263	Substance p and arthritis: analysis of plasma and synovial fluid levels. Arthritis and Rheumatism, 1990, 33, 87-90.	6.7	159
264	Neuromodulation of synovitis: capsaicin effect on severity of experimental arthritis. Journal of Neuroimmunology, 1989, 24, 17-22.	2.3	23
265	Isolated vasculitis of the central nervous system in a patient with celiac disease. American Journal of Medicine, 1986, 81, 1092-1094.	1.5	69
266	Arthritis associated with Haemophilus influenzae meningitis: Septic or reactive?. Journal of Pediatrics, 1986, 109, 412-415.	1.8	25
267	Reactivation of Systemic Lupus in three Patients Undergoing CAPD. Peritoneal Dialysis International, 1986, 6, 6-9.	2.3	15
268	Arthritis, Vasculitis, and Cryoglobulinemia Associated with Relapsing Hepatitis A Virus Infection. Annals of Internal Medicine, 1986, 105, 700.	3.9	102
269	Aseptic arthritis in a man with toxic shock syndrome. Arthritis and Rheumatism, 1986, 29, 910-912.	6.7	11
270	Modulation of mononuclear phagocyte system function and circulating immune complexes by lyophilized concentrates in patients with classic hemophilia. Clinical Immunology and Immunopathology, 1984, 31, 321-330.	2.0	17

#	Article	IF	CITATIONS
271	Clinical and microbial features of prosthetic joint infection. American Journal of Medicine, 1984, 77, 47-53.	1.5	191
272	Induction of polymeric IgA rheumatoid factors in infective endocarditis. American Journal of Medicine, 1983, 75, 785-789.	1.5	22
273	Systemic Lupus Erythematosus in Men. Archives of Internal Medicine, 1982, 142, 1813.	3.8	33
274	Rheumatic manifestations of hepatitis B virus infection. Seminars in Arthritis and Rheumatism, 1982, 11, 406-420.	3.4	63
275	Immune Complexes in SLE. Clinics in Rheumatic Diseases, 1982, 8, 49-62.	1.3	16
276	High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. American Journal of Medicine, 1981, 70, 817-824.	1.5	143
277	Immunologic and clinical aspects of immune complex disease. American Journal of Medicine, 1981, 70, 1097-1106.	1.5	39
278	Isolation and characterization of circulating immune complexes in patients with hepatitis B systemic vasculitis. Clinical Immunology and Immunopathology, 1981, 21, 364-374.	2.0	22
279	Effect of high-dose methylprednisolone infusion on polymorphonuclear leukocyte function in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1981, 24, 641-647.	6.7	19
280	The C1q binding assay in systemic lupus erythematosus. Arthritis and Rheumatism, 1980, 23, 1282-1286.	6.7	35
281	Immunologic sex differences and the female predominance in systemic lupus erythematosus. Arthritis and Rheumatism, 1978, 21, 849-852.	6.7	143